Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could ...

(OTCQX: VXRT) ("Vaxart” or the "Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its ...

Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma -- Licensed SYN-020 to Rasayana Therapeutics ...

The U.S. government and academic labs are pushing multiple universal vaccine candidates through early clinical trials, targeting influenza strains and coronaviruses that mutate faster than today’s ...

Vaxart Inc (VXRT) reports a remarkable revenue increase and strategic collaborations, despite facing challenges in vaccine trial timelines.

Program advancing with guidance from a large pharma collaborator with recognized expertise in this area, with next steps confirming expanded in vitro data including stability testing followed by in ...

This study presents valuable findings that could potentially allow a deeper understanding of the immunopathogenesis underlying influenza infection in aged mice. The results are based on solid evidence ...